-
Benzinga Cannabis Hour Recap: Skye Bioscience CEO Discusses How Cannabinoids May Treat Glaucoma
Thursday, February 11, 2021 - 3:31pm | 527Cannabinoid receptors distributed within the body are part of the endocannabinoid system that largely affects processes such as mood, memory, pain-sensation, and appetite, to name a few. Two types of receptors — CB1 and CB2 — “play a vital role in managing different body...
-
Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids
Friday, December 4, 2020 - 11:17pm | 1198The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids....
-
What's Been Going On With Emerald Bioscience?
Monday, April 8, 2019 - 3:26pm | 595After reporting some strong results from its studies last month, cannabinoid biopharmaceutical company Emerald Bioscience Inc (OTC: EMBI) recently made headlines again. The company formerly known as Nemus Bioscience is in the spotlight following a couple positive announcements, including a...